Key Insights

Highlights

Success Rate

95% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

2.7%

1 terminated out of 37 trials

Success Rate

95.0%

+8.5% vs benchmark

Late-Stage Pipeline

19%

7 trials in Phase 3/4

Results Transparency

37%

7 of 19 completed with results

Key Signals

7 with results95% success

Data Visualizations

Phase Distribution

26Total
Not Applicable (7)
P 1 (6)
P 2 (6)
P 3 (3)
P 4 (4)

Trial Status

Completed19
Unknown8
Not Yet Recruiting4
Recruiting3
Withdrawn2
Terminated1

Trial Success Rate

95.0%

Benchmark: 86.5%

Based on 19 completed trials

Clinical Trials (37)

Showing 20 of 20 trials
NCT05856890Phase 1RecruitingPrimary

HepB mAb19 in Individuals With Chronic Hepatitis B Infection

NCT07267208Phase 2Not Yet RecruitingPrimary

A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT Conversion in Stable Liver Transplant Patients

NCT06881238Recruiting

Impact of Hepatitis B Virus on Inflammatory Bowel Disease

NCT06589518Phase 2Not Yet RecruitingPrimary

To Evaluate the Efficacy and Safety of Tenofovir Alafenamide Conversion in Liver Transplant Patients

NCT06691412Phase 3Not Yet RecruitingPrimary

Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes

NCT04231565Not ApplicableRecruitingPrimary

Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.

NCT03083821Phase 1CompletedPrimary

A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting

NCT04046107Phase 1WithdrawnPrimary

Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy

NCT03625258CompletedPrimary

Mutations of the Pre-core Region of Hepatite B Virus (HBV)

NCT03761875Not ApplicableUnknownPrimary

NK Cell Deregulation in HBV Patients

NCT05752890Not Yet Recruiting

A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma

NCT04072211Phase 4CompletedPrimary

Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District

NCT03459521Not ApplicableCompleted

Efficacy of HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease.

NCT05406089Completed

Effects of Antiviral Therapy on Patients With HBV-related HCC

NCT02785835Completed

Hepatocellular Carcinoma in HIV-infected Patients

NCT02060162CompletedPrimary

Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa

NCT04385524Not ApplicableWithdrawnPrimary

Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection

NCT04850950Phase 4Unknown

Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B

NCT03294798Phase 1CompletedPrimary

Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient

NCT02296853Phase 1CompletedPrimary

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

Scroll to load more

Research Network

Activity Timeline